home / stock / cydy / cydy news

CYDY News and Press, CytoDyn Inc From 07/08/19

Stock Information
Company Name: CytoDyn Inc
Stock Symbol: CYDY
Market: OTC
Website: cytodyn.com
Menu
CYDY CYDY Quote CYDY Short CYDY News CYDY Articles CYDY Message Board
Get CYDY Alerts

News, Short Squeeze, Breakout and More Instantly...
CYDY - New senior science advisor at CytoDyn

CytoDyn ( OTCQB:CYDY ) appoints Dr. Jonah Sacha, Ph.D. as Senior Science Advisor to the Company. More news on: CytoDyn Inc., Healthcare stocks news, Read more ...

CYDY - CytoDyn Names Dr. Jonah Sacha as its Senior Science Advisor to Explore Leronlimab (PRO 140) Potentials in HIV Pre-Exposure Prophylaxis (PrEP) and Cure

VANCOUVER, Washington, July 08, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications tod...

CYDY - CytoDyn Anticipates Revenue Commencing in August 2019 from Use of PA-14 and/or PRO 140 in Diagnostic Test

CytoDyn Signs Non-binding Agreement for Diagnostic License and Supply Agreement with IncellDX for PA-14 and/or  PRO 140 (non-commercial grade) Collaboration represents an immediate revenue opportunity as a diagnostic test for receptor occupancy and the existence of CCR5 on c...

CYDY - FDA grants face-to-face meeting for Cytodyn's ProstaGene Prognostic Test application

The Center for Devices and Radiological Health (“CDRH”) of the FDA has received CytoDyn's ( OTCQB:CYDY ) 510(k) application for clearance of the ProstaGene Prognostic Test. More news on: CytoDyn Inc., Healthcare stocks news, Read more ...

CYDY - FDA Grants Face-to-Face Meeting to Discuss CytoDyn's 510(k) Application for ProstaGene(TM) Prognostic Test

VANCOUVER, Washington, June 24, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications tod...

CYDY - CytoDyn Submits 510(k) Pre-Submission Application to U.S. FDA for ProstaGene(TM) Prognostic Test

VANCOUVER, Washington, June 19, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, to...

CYDY - CytoDyn Announces Major Discovery for its Monotherapy Indication

CytoDyn and IncellDx Report the Successful Development and Validation of an Assay to Assess the Responders for Monotherapy HIV Patients This assay could predict in 2 hours the responder’s rate for a monotherapy patient candidate and the appropriate dose for each patient at the t...
CYDY - CytoDyn Signs Groundbreaking Memorandum of Understanding with Thai Red Cross AIDS Research Centre to Study Pre-Exposure Prophylaxis Use of Leronlimab (PRO 140) in People at High Risk of Acquiring HIV

VANCOUVER, Washington, June 17, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, an...

CYDY - CytoDyn Raises over $12 Million in New Capital from Private and Public Warrant Offers in the Last Five Weeks with Minimum Dilution

VANCOUVER, Washington, June 14, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications ann...

CYDY - CytoDyn to Present Pivotal Data at ASM Microbe 2019 Demonstrating Efficacy and Safety of Leronlimab (PRO 140) in HIV Patients with Multiple ARV Class Resistance

VANCOUVER, Washington, June 13, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications a...
Previous 10 Next 10